Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

T. Rubin, David; Reinisch, Walter; Greuter, Thomas; Gustavo Kotze, Paulo; R.T. Pinheiro, Marcia; Mundayat, Rajiv; S. Maller, Eric; Fellmann, Marc; Lawendy, Nervin; Modesto, Irene; R. Vavricka, Stephan; R. Lichtenstein, Gary

doi:10.1177/17562848211005708

Public

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

Published in Therapeutic Advances in Gastroenterology • Jan 1, 2021

Authors:

David T. Rubin

Walter Reinisch

Thomas Greuter

Abstract

Introduction: Extraintestinal manifestations (EIMs) in patients with ulcerative colitis (UC) are common. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. We evaluated the efficacy of tofacitinib in patients with EIMs, and the impact of tofacitinib on EIMs in pat...

View

Open Access

Subject

Tofacitinib

Ulcerative colitis

Medicine

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!